Lu Lu1, Weixi Xiong2, Xin Yang3, Xudong Ma4, Caiyun Wang5, Bo Yan6, Qin Zhang7, Jie Mu8, Yingying Zhang9, Hui Gao10, Wenyu Liu11, Le Zhang12, Zixiao Li13, Josemir W Sander14, Yongjun Wang15, Dong Zhou16. 1. Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. Electronic address: hxlulu@foxmail.com. 2. Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. Electronic address: 502216168@qq.com. 3. China National Clinical Research Center for Neurological Diseases, Beijing, China; Tiantan Clinical Trial and Research Center for Stroke, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Vascular Neurology, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Electronic address: yaii@qq.com. 4. Department of Healthcare Quality Evaluation, Bureau of Medical Administration, National Health Commission of the People's Republic of China, Beijing, China. Electronic address: 13910092912@163.com. 5. China National Clinical Research Center for Neurological Diseases, Beijing, China. Electronic address: wcaiyun2008@sina.cn. 6. Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. Electronic address: yanbo96@163.com. 7. Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. Electronic address: qinqin198@163.com. 8. Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. Electronic address: mujie2010@foxmail.com. 9. Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. Electronic address: 1689504689@qq.com. 10. Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. Electronic address: gaohui_1008@qq.com. 11. Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. Electronic address: 1183814410@qq.com. 12. Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. Electronic address: 748026031@qq.com. 13. China National Clinical Research Center for Neurological Diseases, Beijing, China; Vascular Neurology, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Electronic address: lizixiao2008@hotmail.com. 14. NIHR University College London Hospitals Biomedical Research Centre, UCL Queen Square Institute of Neurology, London WC1N 3BG & Chalfont Centre for Epilepsy, Chalfont St Peter, SL9 0RJ, United Kingdom; Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede, the Netherlands. Electronic address: l.sander@ucl.ac.uk. 15. China National Clinical Research Center for Neurological Diseases, Beijing, China; Tiantan Clinical Trial and Research Center for Stroke, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Vascular Neurology, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Electronic address: yongjunwang1962@gmail.com. 16. Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. Electronic address: zhoudong66@yahoo.de.
Abstract
PURPOSE: We attempted to determine the nationwide in-hospital mortality rate in people with status epilepticus (SE) in China. METHODS: Using the database of the Chinese Hospital Quality Monitoring System (HQMS), we identified people hospitalised from 2013 to 2017 with an ICD-10 code G41 for SE as the primary diagnosis. HQMS was developed by the National Health Commission of the People's Republic of China. Demographics, outcomes at discharge, and financial information were extracted automatically from the medical records. RESULTS: We identified 29,031 cases with SE as the primary diagnosis from 585 tertiary centres during the five-year period. Among those included, there was a preponderance of men (61 %), and the mean age was 40.4 ± 25.2 years (range: 0-98). The in-hospital mortality rate was 1.46 % over the whole time period, while the overall mortality ranged from 1.80 % in 2013 to 1.20 % in 2017. The mean cost of treatment was 14517.81 RMB ($ 2147.92) per individual, and the mean duration of hospital stay was 9.25 days. CONCLUSION: We provide an overview of mortality related to SE in China as the HQMS database covers a large number of cases of SE in China, making it one of the most efficient tools for mortality investigation. The use of electronic medical records in China creates several challenges and here we discuss lessons learned. The methodology will be improved and will be used in future studies.
PURPOSE: We attempted to determine the nationwide in-hospital mortality rate in people with status epilepticus (SE) in China. METHODS: Using the database of the Chinese Hospital Quality Monitoring System (HQMS), we identified people hospitalised from 2013 to 2017 with an ICD-10 code G41 for SE as the primary diagnosis. HQMS was developed by the National Health Commission of the People's Republic of China. Demographics, outcomes at discharge, and financial information were extracted automatically from the medical records. RESULTS: We identified 29,031 cases with SE as the primary diagnosis from 585 tertiary centres during the five-year period. Among those included, there was a preponderance of men (61 %), and the mean age was 40.4 ± 25.2 years (range: 0-98). The in-hospital mortality rate was 1.46 % over the whole time period, while the overall mortality ranged from 1.80 % in 2013 to 1.20 % in 2017. The mean cost of treatment was 14517.81 RMB ($ 2147.92) per individual, and the mean duration of hospital stay was 9.25 days. CONCLUSION: We provide an overview of mortality related to SE in China as the HQMS database covers a large number of cases of SE in China, making it one of the most efficient tools for mortality investigation. The use of electronic medical records in China creates several challenges and here we discuss lessons learned. The methodology will be improved and will be used in future studies.